Article Text


Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours
  1. A M Jubb1,
  2. T Q Pham1,
  3. A M Hanby2,
  4. G D Frantz1,
  5. F V Peale1,
  6. T D Wu3,
  7. H W Koeppen1,
  8. K J Hillan1
  1. 1Department of Pathology, Genentech Inc, South San Francisco, CA94080, USA
  2. 2Department of Academic Unit of Pathology, University of Leeds, Leeds, UK
  3. 3Department of Bioinformatics, Genentech Inc
  1. Correspondence to:
 A Jubb
 Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA;


Aims: To measure vascular endothelial growth factor (VEGF-A) mRNA in a large, diverse cohort of tumours and to investigate whether VEGF-A expression is associated with markers of hypoxia, including hypoxia inducible factor 1α (HIF-1α) and carbonic anhydrase IX (CA9).

Methods: The expression of VEGF-A and CA9 was assessed in 5067 fresh frozen human tissue samples and 238 cell lines by DNA microarray analysis. In addition, tissue microarrays were constructed from 388 malignancies to investigate the expression of VEGF-A and HIF-1α by in situ hybridisation and immunohistochemistry, respectively.

Results: VEGF-A was significantly upregulated in primary malignancies of the breast, cervix, colon and rectum, oesophagus, head and neck, kidney, ovary, skin, urinary system, and white blood cells by DNA microarray analysis. However, VEGF-A expression only correlated with CA9 expression in renal tissues. In the tissue microarrays, HIF-1α positive cores showed a significant increase in VEGF-A expression in lung, ovary, soft tissue, and thyroid malignancies.

Conclusions: The expression of VEGF-A is upregulated in a large proportion of human malignancies, and may be associated with markers of hypoxia. VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours.

  • vascular endothelial growth factor
  • hypoxia inducible factor one alpha
  • carbonic anhydrase IX
  • angiogenesis
  • neoplasia
  • CA9, carbonic anhydrase IX
  • CHO, Chinese hamster ovary
  • H&E, haematoxylin and eosin
  • HIF-1α, hypoxia inducible factor 1α
  • IHC, immunohistochemistry
  • ISH, in situ hybridisation
  • PCR, polymerase chain reaction
  • TMA, tissue microarray
  • VEGF-A, vascular endothelial growth factor A
  • VHL, von Hippel-Lindau

Statistics from

During tumorigenesis, solid lesions first undergo an avascular phase of growth, until the diffusion of oxygen and the exchange of waste and nutrients become rate limiting.1 The growth and survival of these small colonies (usually <1 mm3) is dependent both on their ability to promote angiogenesis and to adapt to hypoxic conditions.1–4 Indeed, even large tumours suffer from a structurally and functionally abnormal vasculature that results in regions of hypoxia, despite an increase in microvascular density.5

Environments with a low oxygen tension activate a series of transcriptional regulators in human cells, including hypoxia inducible factor 1 (HIF-1).6 HIF-1 is a heterodimeric transcription factor composed of HIF-1α and the constitutively expressed aryl hydrocarbon receptor nuclear translocator (also known as HIF-1β), which are basic helix–loop–helix–PAS domain proteins.7 Both the amount and activity of this heterodimer are kept to a minimum in normoxic cells by a series of oxygen dependent, post translational modifications to the HIF-1α protein.6 The best characterised regulatory mechanism is contingent on protein modification by oxygen dependent prolyl hydroxylases, which is required for binding to a von Hippel-Lindau (VHL) E3 ubiquitin protein ligase that targets HIF-1α for proteasomal degradation.8,9 Under hypoxic conditions, oxygen becomes rate limiting for prolyl hydroxylation,10 and the turnover of HIF-1α decreases accordingly, allowing HIF-1α to accumulate intracellularly.11

“Environments with a low oxygen tension activate a series of transcriptional regulators in human cells, including hypoxia inducible factor 1”

As part of an adaptive physiological response to hypoxia, HIF-1 upregulates the expression of genes that are involved in glycolysis,12–14 erythropoiesis,15 and angiogenesis.12–14,16 Specifically, the promoters 5′ to vascular endothelial growth factor (VEGF-A) and carbonic anhydrase IX (CA9) contain sequences that mediate hypoxia induced transcription and have a high degree of homology to known HIF-1 binding sites (hypoxia response elements).17–20 VEGF-A encodes a proangiogenic ligand, which can transduce angiogenesis through specific tyrosine kinase receptors, principally expressed by angioblasts and endothelial cells.21 The expression of VEGF-A is upregulated to varying degrees in a wide range of human malignancies during tumorigenesis.21 Signalling by growth factors (for example, epithelial growth factor, transforming growth factors α and β, interleukins 1β and 6, platelet derived growth factor, insulin-like growth factor I, and keratinocyte growth factor 1)22–24 and hormones (for example, thyroid stimulating hormone, adrenocorticotrophic hormone, and angiotensin II)25–27 is also implicated in increased transcription of VEGF-A, although the relative contribution of these two mechanisms has yet to be characterised extensively in different tumour types.

High expression of VEGF-A has been associated with a worse survival and an increased incidence of disease recurrence in many malignancies, including cancers of the breast,28–30 colon and rectum,31–35 ovary,36,37 kidney,38 cervix,39 and head and neck.40 HIF-1α activation correlates with a worse prognosis and resistance to treatment in ovarian, head and neck, and oesophageal cancer.41,42 Similarly, CA9 expression is an adverse prognostic indicator in patients with invasive breast carcinoma,43 nasopharyngeal carcinoma,44 cervical carcinoma,45 and non-small cell lung cancer.46 Therefore, accurate and reliable assays of VEGF-A expression and hypoxia have assumed prognostic and therapeutic importance. Nevertheless, none of the techniques used to measure VEGF-A expression has been widely applied, prohibiting reliable interlaboratory comparisons.

The aim of our study was to measure VEGF-A mRNA values in a large, diverse cohort of malignancies. In addition, we sought to investigate the published correlations between VEGF-A expression and markers of hypoxia.


DNA microarray experiments

The Gene Logic® (Gaithersburg, Maryland, USA) database of Affymetrix® HG-U133 GeneChip® probearray data was screened for probes that corresponded to the VEGF-A and CA9 mRNA sequences (Genbank accession numbers M32977 and NM_001216, respectively). Probes with the highest proportion of samples called “present” were chosen for downstream analysis on 7579 fresh frozen human tissue samples and 225 cell lines. (Gene Logic performed tissue sample preparation and data analysis.) Probeset 210512_s_at was chosen to represent VEGF-A expression and probeset 205199_at to represent CA9 expression.

Tissue microarray experiments

Tissue culture

The human tumour cell lines 786-0 (renal cell adenocarcinoma); A673 (rhabdomyosarcoma); SK-MES-1 (lung squamous cell carcinoma); SW480, KM12, HCT15, HCT116, and COLO205 (all human colorectal adenocarcinomas); SkBr3, MDA-MB-453S, MDA-MB-231, MCF7, and MDA-MB-175-VII (all breast adenocarcinomas); and CALU6 (anaplastic carcinoma) were obtained from the American Tissue Culture Collection (Manassas, Virginia, USA). H322 (lung non-small cell carcinoma) was obtained from the National Cancer Institute (Bethesda, Maryland, USA). Chinese hamster ovary (CHO) cells transfected with human VEGF-A were established as described previously.47 Cell lines were cultured in vitro according to the protocols, harvested after the first passage, fixed in 10% neutral buffered formalin, and embedded in paraffin wax.

Selection of human tissues

Formalin fixed, paraffin wax embedded tissue cassettes and corresponding haematoxylin and eosin (H&E) stained sections were retrieved from the histopathology archives at Genentech, South San Francisco, California, USA and the Leeds Teaching Hospitals NHS Trust, UK. (Appropriate ethical approval was obtained for all research conducted using human tissues.) H&E sections were reviewed (KJH) and representative regions of malignant cells were annotated on the slide to aid tissue microarray (TMA) core sampling.

Preparation of synthetic control blocks

cDNA probe templates were generated from human kidney marathon-ready cDNA (BD Clontech, Palo Alto, California, USA). Primers were designed to amplify a 604 bp fragment of VEGF-A mRNA. Sense and antisense primers contained T7 and T3 RNA polymerase initiation sites, respectively (sense, GGATTCTAATACGACTCACTATAGGGCGGGCCTCCGAAACCATGAACT; antisense, CTATGAAATTAACCCTCACTAAAGGGATCCTCCTGCCCGGCTCAC). Each 50 μl polymerase chain reaction (PCR) contained 0.5 ng of cDNA, 33 ng of each primer, 0.6mM dNTPs (0.15mM each dATP, dCTP, dGTP, dTTP), 1× polymerase mix, 1× buffer, and 1.0M GC-Melt (BD Clontech). The thermal cycling conditions were: 94°C for five minutes, followed by 30 cycles of 94°C for one minute and 68°C for 30 seconds. Sense and antisense RNA fragments were transcribed from this template using T7 and T3 RNA Megascript kits, respectively (Ambion, Austin, Texas, USA). Fragments were embedded in 2% agarose at a concentration of 5 μg/ml, and processed as described previously.48 Blank 2% agarose controls were processed in an identical manner.

Tissue microarray construction

TMAs were constructed to represent the case series using a Beecher Instruments’ microarrayer (Silver Spring, Maryland, USA), as described previously.49 In total, 388 tissues were sampled (three adrenal, 83 breast, two endometrium, three kidney, three liver, 78 lung, 71 ovary, four pancreas, 78 soft tissue, and 63 thyroid), in addition to the cell pellets and synthetic control blocks described above. Tissue sampling was undertaken in triplicate to provide representative data on the parent block50; synthetic controls and cell pellets were sampled in duplicate. Sections, 3 μm thick, were cut from the recipient blocks and mounted on to glass slides. H&E staining for verification of the histology (KJH) was performed on the first section cut from each TMA block.


Tissue sections were dewaxed and heat mediated antigen retrieval was performed in target retrieval solution (Dako Cytomation, Carpinteria, California, USA). Immunohistochemistry (IHC) was carried out as described previously,51 using a primary antihuman HIF-1α monoclonal antibody at 1 μg/ml, (clone H1α67; Novus Biologicals, Littleton, Colorado, USA). Negative control slides were incubated with a mouse IgG2b immunoglobulin culture supernatant (Dako Cytomation) at 1 μg/ml. Cases were assigned as positive for HIF-1α if one or more of the three cores contained neoplastic cells with positively staining nuclei (KJH).

In situ hybridisation

For each riboprobe to be synthesised, 12 μl (125 mCi) of [α33P]-UTP (Amersham Biosciences, Piscataway, New Jersey, USA) was speed vacuumed until dry. Each aliquot was reconstituted in 1× buffer, 4.5mM dithiothreitol, 0.23mM rNTPs (0.08mM each rATP, rCTP, rGTP), 2.3μM rUTP, 1.4 U/μl RNAse inhibitor, 0.05 μg/μl cDNA template, and 0.7 U/μl of either T7 (sense probe) or T3 (antisense probe) RNA polymerase (Promega, Madison, Wisconsin, USA). In vitro transcription took place over one hour at 37°C. Samples were then treated with 0.05 U/μl DNase (Promega) for 15 minutes at 37°C and purified over RNeasy mini columns (Qiagen, Valencia, California, USA). Formalin fixed, paraffin wax embedded tissue sections were dewaxed and treated with proteinase K (20 μg/ml in 2× SSC) at 37°C for 15 minutes. Hybridisation and washes were carried out as described previously.48,52,53

Tissue sections were dehydrated, air dried, and exposed to a phosphorscreen for 16 hours at room temperature. Immediately after incubation, the phosphorscreen was scanned with a Typhoon 9410 (Amersham Biosciences, Piscataway, New Jersey, USA). Slides were then dipped in NBT2 nuclear track emulsion (Eastman Kodak, Rochester, New York, USA), exposed for four weeks at 4°C, developed, and counterstained with H&E. Background subtraction, gridding, and analysis of the phosphorimages were undertaken with Phoretix Array v.3 (Nonlinear Dynamics, Newcastle upon Tyne, UK). Subsequently, the TMAs were reviewed (KJH) by bright/dark field microscopy for verification of hybridisation. Cores were scored semiquantitatively on a scale of 0 (no expression) to 3 (very strong signal), according to the overall intensity of the hybridisation signal.

Statistical analysis

Statistical analysis was performed using SPSS for Windows (version 11.0; Chicago, Illinois, USA). The Mann-Whitney U test was used to assess the differences between the median values of continuous datasets. Large datasets were subjected to false discovery rate controlling procedures as indicated.54 Significance was assumed if the two sided p value was < 0.05 and the false discovery rate controlling procedure did not discount the finding.


DNA microarray data

VEGF-A expression

When compared with normal tissue, median VEGF-A expression was significantly greater in primary malignancies of the breast (1.4 fold), cervix (1.4 fold), colon and rectum (2.2 fold), oesophagus (2.0 fold), head and neck (1.6 fold), kidney (3.2 fold), ovary (3.5 fold), skin (1.6 fold), urinary system (3.1 fold), and white blood cells (7.8 fold; including acute lymphocytic leukaemia and chronic myeloid leukaemia spleen samples) (fig 1; table 1). Malignancies of the kidney showed the greatest range and maximum expression of VEGF-A (fig 1). VEGF-A was further upregulated in metastatic colorectal tumours when compared with primary malignancies with no evidence of metastasis (table 1). This association was not seen in other tumour types. In contrast, significant reductions of VEGF-A, relative to normal tissue, were noted in primary malignancies of the lymphoid system (median 0.24 of normal), prostate (0.65 of normal), stomach (0.77 of normal), testis (0.29 of normal), and thyroid (0.44 of normal) (fig 1; table 1).

Table 1

Relative degree of vascular endothelial growth factor A mRNA expression determined by DNA microarray analysis (probe 210512_s_at) in different tissues and pathological states

Figure 1

Electronic northern plot of the relative degrees of vascular endothelial growth factor A (VEGF-A) mRNA expression in different tissues and pathological states, determined by DNA microarray analysis (probeset 210512_s_at). The box represents the interquartile range, divided by a median line. Green, normal tissue; red, malignant tissue; blue, non-malignant disease. The Mann-Whitney U test was used to assess the differences between the median values of normal and primary malignant tissue: *p < 0.05; **p < 0.01; ***p < 0.0001. CNS, central nervous system; WBC, white blood cells.

VEGF-A v CA9 expression

The degree of CA9 expression showed a linear correlation with that of VEGF-A only in renal tissue (R2  =  0.54; fig 2A). The correlation was strongest in neoplastic tissues (R2  =  0.38), with a weaker association in normal kidney (R2  =  0.26), and no correlation in non-malignant disease (R2  =  0.01). Correlations were not apparent in breast, colorectal, lung, ovary, pancreas, prostate, thyroid, or urinary tissues (fig 2B).

Figure 2

Scatter plots comparing the expression of vascular endothelial growth factor A (VEGF-A) and carbonic anhydrase IX (CA9) mRNA, assessed by DNA microarray in (A) kidney tissues and (B) breast, colorectal, lung, ovary, pancreas, prostate, thyroid, and urinary tissues.

Tissue microarray data

VEGF-A expression

To corroborate the Gene Logic data on tissue homogenates, we undertook an investigation of VEGF-A expression by in situ hybridisation (ISH) on a series of human tumour samples. VEGF-A expression was seen in the stromal and/or neoplastic cell populations of positive (score 1–3) TMA cores covering a range of malignancies (fig 3). The ISH score given by the pathologist correlated closely with the quantitative signal obtained by phosphorimaging, which has been used for the remainder of the analysis (fig 4). The VEGF-A antisense control recorded a positive signal by phosphorimaging, when compared with the VEGF-A sense and blank agarose negative controls (fig 5). Of the cell pellets, the VEGF-A transfected CHO cells showed the highest quantitative signal intensity, with lower signals in 786-0, A673, SKMES, SW480, and KM12 cells (fig 5). The remaining cell lines expressed little or no VEGF-A.

Figure 3

Tissue microarray cores illustrating vascular endothelial growth factor A (VEGF-A) in situ hybridisation (ISH) and hypoxia inducible factor 1α (HIF-1α) immunohistochemistry. Brightfield and darkfield images of VEGF-A ISH demonstrate silver grains overlying neoplastic cells (red arrows). (A) Renal adenocarcinoma; (B and E) lung squamous cell carcinoma; (C and D) lung adenocarcinoma. Bars: 100 μm except for high power images (20 μm). Low power and high power images of HIF-1α immunohistochemistry show nuclear localisation of the diaminobenzidine chromagen in stromal (D) and neoplastic (A, B, and E) cell populations. VEGF-A expression can be seen in both HIF-1α positive (A, B, and E) and negative (C and D) tissue cores.

Figure 4

Box plots showing the distribution of quantitative data obtained by phosphorscreen imaging of vascular endothelial growth factor A (VEGF-A) in situ hybridisation studies, classified according to the histopathologist’s score. The box represents the interquartile range, divided by a median line. Whisker lines delineate the number of cases that lie within 1.5 box lengths from the upper or lower extremes of the interquartile range. Empty circles represent outliers found within 1.5 and 3 box lengths from the upper or lower extremes of the interquartile range. Solid circles mark extreme values outside of this range.

Figure 5

Quantitative vascular endothelial growth factor A (VEGF-A) mRNA expression assessed by in situ hybridisation phosphorimage analysis in a series of cell pellets and synthetic controls. VEGF-A-S, VEGF-A sense; VEGF-A-AS, VEGF-A antisense.

VEGF-A v HIF-1α expression

Of 1025 tumour cores, 316 (31%) scored positive for HIF-1α expression in the nuclei of the stromal and/or neoplastic cell populations. All nine cores of renal cell carcinoma and follicular adenocarcinoma of the thyroid were positive, compared with only 5% of breast ductal adenocarcinomas, 4% of mucinous ovarian adenocarcinomas, 6% of gastrointestinal stromal tumours, and no adenocarcinomas of the endometrium or neuroendocrine tumours of the lung (table 2). HIF-1α positive cores showed significantly higher VEGF-A expression than did HIF-1α negative cores in adenocarcinomas of the lung (1.6 fold), serous adenocarcinomas of the ovary (4.5 fold), liposarcomas (20.5 fold), rhabdomyosarcomas (4.8 fold), and medullary carcinomas of the thyroid (1.7 fold) (table 2).

Table 2

Relative VEGF-A mRNA expression determined by quantitative in situ hybridisation in different tumour types


The measurement of VEGF-A expression in tumours has become an important methodological issue in determining prognosis,28–40 and may affect the sensitivity of individual tumours to targeted antibody and small molecule treatments. At present, there is a large body of literature describing the changes in VEGF-A expression during tumorigenesis, using many different techniques, such as ISH,48,55 IHC,30,37,40,56,57 enzyme immunoassay,58 reverse transcription-PCR,36,40 and western blotting.40 However, none of the techniques used to measure VEGF-A expression has been widely applied,59 and there is no accepted gold standard. This limits the external validity of studies and prohibits reliable interlaboratory comparisons. In addressing this concern, we used both DNA microarray and TMA technology to investigate the expression of VEGF-A in a large series of diverse human tumours. Furthermore, the data yielded information on the proportion of tumours in which the upregulation of VEGF-A expression is associated with markers of hypoxia.

A key aim of our study was to appraise the prevalence and degree of VEGF-A upregulation in a large series of diverse tumour types. DNA microarray analysis demonstrated a significant increase in median VEGF-A expression in many prevalent types of malignancy (fig 1; table 1). The data fall within the range of VEGF-A expression reported for these tumour types in the literature.28–40,48 In addition, there is a significant increase in VEGF-A expression in colorectal adenomas compared with normal colorectal tissue, which has been reported previously by our group48 and by independent investigators.60 However, not all tumours upregulate VEGF-A expression at the mRNA level. For example, DNA microarray analysis demonstrated a significant downregulation of VEGF-A expression in benign prostatic hypertrophy and primary malignancies of the lymphoid system, prostate, stomach, testis, and thyroid. Furthermore, the Gene Logic series of metastatic breast cancers did not show a significant increase in VEGF-A expression when compared with primary malignancies or normal breast. These observations are not supported by the literature,61–68 which may be a reflection of publication bias towards positive findings, demographic differences, or experimental idiosyncrasies. Limitations of the Gene Logic data include low sample numbers for certain tumour types. Moreover, many samples of normal tissue were obtained from tumour resection margins, which may be under the influence of paracrine and hormonal factors secreted by the tumour. For example, in testicular cancer this adjacent tissue frequently shows other histopathological changes. Nevertheless, analyses on subsets of normal tissue of the colon, ovary, breast, lung, and cervix showed no significant differences in VEGF-A expression between tissue from patients with or without cancer (data not shown). This paper also focuses on the expression of VEGF-A mRNA, in contrast to the published literature, which has relied more heavily on immunohistochemistry.61–66 Although mRNA transcript abundance is not always a true reflection of changes in protein expression, the interpretation of immunohistochemistry is complicated by the specificity and sensitivity of the antibody used. In addition, it is possible that tumours in which VEGF-A is not upregulated trigger the angiogenic switch by either downregulating antiangiogenic factors or upregulating other proangiogenic factors, circumventing their requirement for VEGF-A. For example, angiopoietin-2, a proangiogenic ligand, is upregulated in thyroid cancers and thrombospondin-1, an antiangiogenic extracellular matrix component, is downregulated.61

Take home messages

  • Vascular endothelial growth factor A (VEGF-A) expression is upregulated in a large number of human malignancies, and may be associated with markers of hypoxia

  • VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours

“DNA microarray analysis demonstrated a significant downregulation of vascular endothelial growth factor A expression in benign prostatic hypertrophy and primary malignancies of the lymphoid system, prostate, stomach, testis, and thyroid”

In the canonical model outlined above, the expression of VEGF-A is a result of increased transcriptional activity in response to HIF-1α activation under hypoxic conditions.6 However, the data presented here indicate that a large proportion of malignancies exhibit VEGF-A upregulation in the absence of these markers of hypoxia. Although the canonical model holds true in some tumours, it seems short sighted to view it as the only means of VEGF-A upregulation in human cancer. In adenocarcinomas of the kidney, the relatively strong association of HIF-1α and CA9 with VEGF-A may result from reduced HIF-1α turnover as a result of mutations or promoter methylation of the VHL gene, reported in 56% of sporadic clear cell carcinomas.66 A similar association between HIF-1α and VEGF-A expression was seen for lung tumours, serous adenocarcinomas of the ovary, liposarcomas, rhabdomyosarcomas, and medullary carcinomas of the thyroid. However, the last three tumour types were not well represented in our study and our findings need to be confirmed in a larger series. Furthermore, we suggest that many tumours may exploit hypoxia independent mechanisms to increase their expression of VEGF-A, which is also regulated by certain growth factors and/or hormones known to be manipulated during tumorigenesis.25–27

In summary, the data presented here represent the largest single series of human tissues and pathologies profiled for VEGF-A expression in a uniform and quantitative manner. The findings may prove useful in establishing a reference for VEGF-A expression in malignant disease.


We gratefully acknowledge the assistance of P Tobin, B Wright (Department of Pathology, Genentech Inc), K Jung (Department of Bioinformatics, Genentech Inc), and M Ostland (Department of Biostatistics, Genentech Inc).


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.